Parliamentary Search

Written question asked by Lord Mendelsohn (Labour) on Thursday, 16 July 2026, in the House of Lords. It was due for an answer on Thursday, 30 July 2026. It was answered by Baroness Merron (Labour) on Wednesday, 9 September 2026 on behalf of the Department of Health and Social Care.

Blood Cancer: Health Services

Question

To ask His Majesty's Government what assessment they have made of the potential role of minimal residual disease testing in supporting more personalised treatment pathways for blood cancer patients.

Answer

The Government is committed to ensuring blood cancer patients can benefit from more personalised approaches to treatment where these are supported by the best available evidence.

The National Cancer Plan sets out how we will support this through expanding access to genomics, modernising diagnostic services, and accelerating the adoption of evidence-based innovation across the National Health Service. By 2028, genomic data will be integrated into the unified genomic record as part of the Single Patient Record, enabling clinicians to identify the most effective treatment pathway more quickly.

Decisions on the commissioning and adoption of individual tests and treatments are informed by the available clinical evidence and are the responsibility of NHS England. Decisions about an individual's treatment are made by clinicians and multidisciplinary teams, taking account of the patient's clinical circumstances.

Secondary information

Type
Written question
Reference
HL2209
Session
2026-27
Grouped for answer
Yes
Subjects
Health services Testing Blood cancer
Link
View this Written question on www.parliament.uk